Elanco Animal Health, Inc. (ELAN)
24.50
+0.08
(+0.33%)
USD |
NYSE |
Sep 04, 16:00
24.47
-0.03
(-0.12%)
Pre-Market: 20:00
Elanco Animal Health Research and Development Expense (Quarterly) : 92.00M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 92.00M |
| March 31, 2026 | 97.00M |
| December 31, 2025 | 93.00M |
| September 30, 2025 | 89.00M |
| June 30, 2025 | 92.00M |
| March 31, 2025 | 94.00M |
| December 31, 2024 | 81.00M |
| September 30, 2024 | 87.00M |
| June 30, 2024 | 89.00M |
| March 31, 2024 | 87.00M |
| December 31, 2023 | 79.00M |
| September 30, 2023 | 86.00M |
| June 30, 2023 | 81.00M |
| March 31, 2023 | 81.00M |
| December 31, 2022 | 80.00M |
| September 30, 2022 | 78.00M |
| June 30, 2022 | 82.00M |
| Date | Value |
|---|---|
| March 31, 2022 | 81.00M |
| December 31, 2021 | 92.00M |
| September 30, 2021 | 94.00M |
| June 30, 2021 | 94.00M |
| March 31, 2021 | 89.00M |
| December 31, 2020 | 112.70M |
| September 30, 2020 | 88.10M |
| June 30, 2020 | 59.40M |
| March 31, 2020 | 66.80M |
| December 31, 2019 | 67.30M |
| September 30, 2019 | 69.90M |
| June 30, 2019 | 68.80M |
| March 31, 2019 | 64.10M |
| December 31, 2018 | 61.10M |
| September 30, 2018 | 58.90M |
| June 30, 2018 | 61.40M |
| March 31, 2018 | 65.20M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.819B |
| Zoetis, Inc. | 173.00M |
| ANI Pharmaceuticals, Inc. | 14.75M |
| EyePoint, Inc. | 83.61M |
| Amylyx Pharmaceuticals, Inc. | 23.72M |